Latest news with #AndrewNewland
Yahoo
20 hours ago
- Business
- Yahoo
Angle PLC Announces Posting of Annual Report and Notice of AGM
GUILDFORD, SURREY / / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2024, and the Notice of Annual General Meeting ("AGM") within it, have been posted to shareholders, and are available on the Company's website. The AGM will be held at 2:00 pm on Monday 30 June 2025 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 hours ago
- Business
- Yahoo
Angle PLC Announces Posting of Annual Report and Notice of AGM
GUILDFORD, SURREY / / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2024, and the Notice of Annual General Meeting ("AGM") within it, have been posted to shareholders, and are available on the Company's website. The AGM will be held at 2:00 pm on Monday 30 June 2025 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wales Online
a day ago
- Wales Online
Beautiful Romany wagon tucked away in wildflower meadow by river with brown trout and otters
Beautiful Romany wagon tucked away in wildflower meadow by river with brown trout and otters A truly unique 'tranquil and enchanting' site that sadly the owners are now forced to take to auction Not your usual property for sale (Image: Morgan & Davies Aberaeron / Auction House Wales ) Have you ever experienced the arguably very stressful scenario of buying a property without even seeing it in reality? Andrew Newland from Pontypridd and Alexandra from Mold have done it - three times - and one of the unseen purchases was as unique as the situation. After spending 14 years living and teaching in Asia teaching in China, Thailand, Vietnam and lastly Hong Kong, the couple were ready to come home to Wales to re-establish roots for raising a family. The pair were looking for a business to buy with their friends John and Rachel, and stumbled across surely one of the most wonderful and wild holiday lets in west Wales - a pocket of land that is home to a genuine Romany wagon as well as a wooden cabin and pretty slice of land. For more property stories sent to your inbox twice a week sign up to the property newsletter here. READ MORE: We transformed an old cow shed into an incredible Welsh home ALSO: Stunning country manor with cottages and over 500 acres of land for sale for £4.5m The Romany Gypsy Wagon is joined on the site by a wooden chalet (Image: Morgan & Davies Aberaeron / Auction House Wales ) Article continues below Andrew says: " We hadn't actually seen the place, we were still in Hong Kong when we bought it - we sent our in-laws as scouts and they had a good look around for us and they fell in love with the place - it's unique - just under an acre and where the wagon and cabin are and then separate flower meadow connected by a small bridge that we built and there's a section of river that flows through the site with trout and salmon and otters. "Family and friends thought we were 'a bit mad' but they know us and in life we've taken the road less travelled, so it was very 'on brand' for us." But as soon as the couple visited the site near Llangrannog, Ceredigion they were enchanted. Andrew remembers: " We were immediately taken by it - there was a storm, my wife was heavily pregnant with our second child and the phone signal is not very good and there's no WiFi but even with all that we fell in love with the place. The site is 0.65 acres in size (Image: Morgan & Davies Aberaeron / Auction House Wales ) "It's the silence - the fact it was totally cut off - such a difference to what we were used to, to Hong Kong - to come into that, a slice of heaven in Wales. It's where time slows down. "I love the wagon most of all, it's almost womb-like! Because the cover is all insulated you're cosseted from sound as well so it's very much how I imagine what a womb is like. It's got a nice big comfy bed and heating, room under the bed to fit a dog bed too if visitors want to bring their dog away with them. Idyllic and peaceful place to relax near Llangrannog, Ceredigion (Image: Morgan & Davies Aberaeron / Auction House Wales ) "The wagon is one of the main reasons why the site got planning permission as a holiday let - because of the historical value of the wagon itself, it's a genuine vintage Romany wagon. And i t's a stunning location even if the weather is not great, you can still lie in bed, read a book with the top half of the wagon door open and watch the rain." The site comes with a wooden cabin too that offers a kitchenette with bistro table and chairs and an amazing view from the kitchen sink, a shower room and a lounge which opens out onto a new raised deck area, one of the features the couple have worked on since owning the site, as well as tidying the foliage, renovating the paths, painting the wagon and building a bridge over the little river. The Romany gypsy wagon looks very inviting (Image: Morgan & Davies Aberaeron / Auction House Wales ) Andrew says: "You come out of the cabin in the morning with your coffee and you sit there and you feel like you're in the trees, you're well above the wagon and above the river so you're up mid-tree level - you're in amongst the birds - there are so many fantastic birds there - we fill the feeders and watch them and that's all you can hear, the bird song and the river." But not seeing the site before they bought it was not the challenge for the couple. It is said by many people that timing is important with a property purchase and for Andrew and Alex it was bad timing - they came back to Wales and were the new owners of the site in December 2019, just a few months before the Covid-19 pandemic hit. Inside the wagon is comfortable and cosy (Image: Morgan & Davies Aberaeron / Auction House Wales ) Andrew, a retrofit assessor, says the situation wiped out the first 18 months of running the tranquil and secluded site as a successful holiday let and led to a change of plan and location for the family. He says: " We were going to come back home and set up a holistic fitness retreat, run it from the land and develop it further and have more accommodation but we had to make other plans and so I started a business near Chester so we ended up being based in north Wales." The site also contains a wood chalet which is also part of the auction lot (Image: Morgan & Davies Aberaeron / Auction House Wales ) The two couples ran the holiday let business via and trying to visit the site as much as possible to keep it maintained and also stay and enjoy it themselves occasionally. Andrew says: "People love it as much as we do which is fantastic, everybody who comes to stay seems to have the same experience - people feel like they are transported back to a simpler time - lack of phone signal, lack of WiFi, it taps into a sense of nostalgia." Inside the chalet and it's surprisingly spacious with a kitchenette and cost lounge (Image: Morgan & Davies Aberaeron / Auction House Wales ) The site has even attracted the attention of TV presenter and celebrity Richard Hammond, who stayed back in 2007 before the two couples owned it and it was booked via company Under The Thatch, said: "It was only in the morning that I fully appreciated why this place is so popular. "Although the caravan scores high on novelty points, it's the setting that's the real winner. Tucked away in the corner of a wild-flower meadow next to the river where brown trout and otter are protected as part of a Site of Special Scientific Interest, it's secluded and ridiculously picturesque." The cute kitchen also has space to eat at a bistro table (Image: Morgan & Davies Aberaeron / Auction House Wales ) However after a few years making the three to four hour journey from north Wales to this special spot near the Ceredigion coast it is with heavy hearts the two couples have decided to sell the site and pass on this idyllic and enchanting site on to a new owner, who has the chance to realise its potential to expand the business into the land and increase the size of the cabin, subject to planning of course, and if they want to. Andrew says the experience has taught them the value of owning a holiday let and says if someone is thinking of purchasing the site, or any other unique property, they should consider what makes it distinctive in the first place, and cherish it. For more property stories join our Amazing Welsh Homes Facebook group here The chalet can even boast a shower room with full facilities (Image: Morgan & Davies Aberaeron / Auction House Wales ) He says: "Try and maintain the character of the place. It would have been easy for us to tear the cabin down, to remove the wagon, and put on some standard glamping facility but we wanted to maintain the character of the place - we wanted to keep it authentic, that's what we strived for. "Keep the authenticity of the place and then it rings true to everybody who comes. Oh, and make sure it's not a four hour drive away, get one closer to where you live!" The 0.65 acre site, including the wagon and the cabin, is going to auction with a guide price of £99,000 with Auction House Wales with bidding opening on Monday June 23 at noon and finishing on Wednesday June 25 at 12.36pm, call 01633 212555 to find out more. Viewings are strictly via appointment with the local agent Morgan and Davies, Aberaeron, call 01545 571600 to find out more. The chalet's wooden deck is a sun-kissed bonus feature perfect for alfresco dining or star-gazing (Image: Morgan & Davies Aberaeron / Auction House Wales ) Andrew says: "Selling is definitely bittersweet for us. It holds a lot of emotional value, and parting with it isn't easy. That said, it's a necessary step for the next phase of our lives, which we're genuinely excited about. "While there's some sadness and disappointment in letting it go, we're also happy knowing that someone else will have the chance to realise the full potential of the site. It's a special place, and we hope the new owners will love it as much as we have." Article continues below Find your own holiday let or property for sale in Wales:
Yahoo
30-05-2025
- Business
- Yahoo
ANGLE PLC (ANPCY) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Revenue Growth: 31% increase in 2024 compared to 2023. Gross Margin: Maintained at approximately 62%. Operating Expenditure: Reduced by 21%. Net Loss Reduction: Decreased by 29%. Cash Runway: GBP11.6 million, lasting into Q1 2026. Fundraising: Raised GBP9.3 million gross in June 2024. Pharma Contracts: Secured three large pharma contracts and one large biopharma contract. Potential Revenue from Trials: GBP1 million to GBP4 million for Phase 2 trials; GBP15 million to GBP45 million for Phase 3 trials. Companion Diagnostic Revenue Potential: Estimated at GBP20 million annually per program. Warning! GuruFocus has detected 2 Warning Signs with ANPCY. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ANGLE PLC (ANPCY) achieved a 31% growth in revenues for 2024 compared to 2023, despite adverse market conditions. The company successfully secured three large pharma contracts and one large biopharma contract, with all progressing well and concluding successfully. ANGLE PLC (ANPCY) developed a new DNA dual analysis method, offering unique insights by analyzing both living cancer cells and fragments of dead cells. The company reduced operating expenditure by 21%, contributing to a 29% reduction in losses. ANGLE PLC (ANPCY) has over 100 peer-reviewed publications from independent cancer centers validating the effectiveness of its Parsortix system. There are delays in decision-making from large pharma companies, affecting the timing of potential contracts. The company faces challenges due to the tightening funding environment, impacting smaller biopharma companies and delaying some projects. Uncertainty in research funding, particularly in the US, is causing delays in purchasing decisions from research institutions. The company is experiencing delays in the procurement process in Europe, even when they are the preferred vendor. ANGLE PLC (ANPCY) faces competition from established methods like circulating tumor DNA (CT-DNA) analysis, requiring significant market education efforts. Q: Can you give us a sense of how discussions with potential medtech partners are going and the size of the opportunity compared to pharma? A: Andrew Newland, Chief Executive, explained that while pharma has a defined process for clinical trials, medtech opportunities, though fewer, can be substantial. Medtech companies are interested in using Parsortix for repeat testing, which could significantly expand their revenue opportunities. The cost of tissue biopsy in metastatic breast cancer is high, and Parsortix offers a cheaper alternative. Q: Have you seen evidence of project cancellations or delays affecting the business? A: Ian Griffiths, Chief Financial Officer, noted that there have been some delays, such as Eisai handing back a project to BlissBio. This creates uncertainty, but discussions with BlissBio are ongoing. The pipeline is building, but decision-making has been slower due to market conditions. Q: Does your cash runway through Q1 2026 assume further cost reductions? A: Ian Griffiths stated that while they continue to manage costs, investments in the clinical lab are necessary to meet the requirements of large clients like AstraZeneca. They aim to keep the cost base tight while ensuring they have the capacity to deliver. Q: Is there a Parsortix product development pipeline, and what does it look like? A: Andrew Newland mentioned that the focus is on developing uses for cancer cells rather than the instrumentation itself. The Parsortix system is stable, and development work is centered on methods to analyze cancer cells, funded mainly by customers. Q: Are large pharma opportunities more about educating them on CTC technology or competition with CT-DNA? A: Andrew Newland explained that educating pharma about CTCs is crucial. Some may not be familiar with CTCs or have had past experiences with older systems. Demonstrating the advantages of Parsortix and providing data is key to gaining their interest. Q: How are tariffs affecting your business? A: Ian Griffiths noted that tariffs in the US are passed directly to customers, as Angle has a unique offering that cannot absorb these costs. Customers accept this as part of dealing with Angle. Q: Do you have visibility on when funding for basic research might open up again? A: Ian Griffiths stated that there is uncertainty due to potential budget cuts in the US. Some institutions may secure funds from other sources, but government institutions might struggle, affecting their ability to fund projects. Q: Do you have visibility on when large pharma like AstraZeneca will make decisions? A: Ian Griffiths acknowledged the challenge in predicting timing. While the pipeline is strong, uncertainty in the environment means they must be cautious in their expectations. Revenue recognition will also be spread over time once deals are signed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Angle PLC Announces Notice of Results
Notice of Preliminary Results and Webcast GUILDFORD, SURREY / / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its preliminary results for the year ended 31 December 2024 on Wednesday 28 May 2025. A meeting for analysts will be held at 11:00 am BST on Wednesday 28 May 2025 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. A live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Berenberg (NOMAD and Corporate Broker)Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI ConsultingSimon Conway, Sam PurewalMatthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
